When is a bubble not a bubble but a fundamental and lasting shift in investor sentiment towards a sector? Despite repeated calls from the biotech bear camp that the end is in sight for the continued optimism enjoyed by the sector we continue to enjoy a burst of IPOs, fundraisings and M&A deals.
03 Aug 2015
Life Sciences Review - The Biotech Feast - after the party comes the hangover
Eden Research plc (EDEN:LON), 13.0 | Motif Bio Plc (MTFB:LON), 0.5 | Tiziana Life Sciences PLC (TILS:LON), 162 | SDI Group plc (SDI:LON), 116 | Genedrive Plc (GDR:LON), 49.0 | ImmuPharma plc (IMM:LON), 11.8 | Benchmark Holdings Plc (BMK:LON), 61.2 | Advanced Oncotherapy Plc (AVO:LON), 40.5 | Avacta Group PLC (AVCT:LON), 145
-
-
-
Derren Nathan
-
10 pages
-


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Life Sciences Review - The Biotech Feast - after the party comes the hangover
Eden Research plc (EDEN:LON), 13.0 | Motif Bio Plc (MTFB:LON), 0.5 | Tiziana Life Sciences PLC (TILS:LON), 162 | SDI Group plc (SDI:LON), 116 | Genedrive Plc (GDR:LON), 49.0 | ImmuPharma plc (IMM:LON), 11.8 | Benchmark Holdings Plc (BMK:LON), 61.2 | Advanced Oncotherapy Plc (AVO:LON), 40.5 | Avacta Group PLC (AVCT:LON), 145
- Published:
03 Aug 2015 -
Author:
Derren Nathan -
Pages:
10 -
When is a bubble not a bubble but a fundamental and lasting shift in investor sentiment towards a sector? Despite repeated calls from the biotech bear camp that the end is in sight for the continued optimism enjoyed by the sector we continue to enjoy a burst of IPOs, fundraisings and M&A deals.